Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Core Viewpoint - Aptose Biosciences Inc. has been determined by the Nasdaq Hearings Panel to delist its common shares from Nasdaq due to non-compliance with the Exchange's equity requirement by the deadline of March 31, 2025 [1] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor aimed at treating acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy for newly diagnosed AML patients [3] Delisting Details - The Nasdaq Hearings Panel's decision was based on Aptose's failure to demonstrate compliance with the equity requirement outlined in Listing Rule 5550(b)(1) by the specified date [1] - Trading of Aptose's common shares will be suspended effective April 2, 2025, following the Panel's determination [1] Future Plans - The company and its board are considering all available options, including an appeal against the delisting decision, while continuing to execute its business plan [2] - Aptose intends to seek a listing on a U.S. national Securities Exchange at an appropriate time [2]